Drugs / MEDI-534
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00345670 | Jun 2006 → May 2007 | — | MedImmune LLC | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00686075 | Jun 2008 → Aug 2012 | — | MedImmune LLC | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT00493285 Comparator | Jul 2007 → Nov 2009 | parainfluenza virus type 3 infectious disease, respiratory syncytial virus infectious disease | MedImmune LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MEDI-534 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00686075 ↗ |
| Modality | Vaccine | “a Live, Attenuated Intranasal Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3)” NCT00345670 ↗ |
| Route | Intranasal | “will be administered on Study Day 0 by nasal spray” NCT00345670 ↗ |